MCID: VCC001
MIFTS: 49

Vaccinia

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Vaccinia

MalaCards integrated aliases for Vaccinia:

Name: Vaccinia 12 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3298
MeSH 43 D014615
SNOMED-CT 67 111852003
UMLS 71 C0042214

Summaries for Vaccinia

Disease Ontology : 12 A viral infectious disease that results in infection, located in skin, has material basis in Vaccinia virus, which is used as a live vaccine against smallpox. The virus is transmitted by contact with the vaccination site before it has healed, or transmitted by fomites that have been contaminated with live virus from the vaccination site. The infection has symptom rash, has symptom fever, and has symptom body aches.

MalaCards based summary : Vaccinia is related to variola major and herpes simplex, and has symptoms including fever, rash and body aches. An important gene associated with Vaccinia is VRK1 (VRK Serine/Threonine Kinase 1), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Sorafenib and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and prostate, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It... more...

Related Diseases for Vaccinia

Diseases related to Vaccinia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 383)
# Related Disease Score Top Affiliating Genes
1 variola major 32.4 DUSP3 CYB5R3
2 herpes simplex 31.7 IRF3 IFNA1 EIF2S1 EIF2AK2
3 stomatitis 31.3 IL2 IFNA1 EIF2AK2 CSF2
4 measles 31.3 IRF3 IL2 IFNA1 EIF2AK2
5 newcastle disease 31.1 IRF3 IFNA1 EIF2S1 EIF2AK2
6 severe acute respiratory syndrome 31.1 IRF3 IL2 IFNA1
7 influenza 31.0 IRF3 IFNA1 EIF2S1 EIF2AK2
8 mumps 30.9 IL2 IFNA1 EIF2AK2
9 exanthem 30.8 IL2 IFNA1 CSF2
10 viral infectious disease 30.8 IRF3 IL2 IFNA1 EIF2S1 EIF2AK2
11 immune deficiency disease 30.8 IL2 IFNA1 EIF2AK2 CSF2 CD80 BANF1
12 diphtheria 30.2 IL2 IFNA1 CSF2
13 autoimmune disease 30.0 NLRP1 IL2 IFNA1 CSF2 CD80
14 mucositis 30.0 IL2 IFNA1 CSF2
15 human immunodeficiency virus infectious disease 30.0 IL2 IFNA1 CSF2 CD80
16 myocarditis 29.8 IL2 IFNA1 CD80
17 cowpox 11.7
18 smallpox 11.1
19 human immunodeficiency virus type 1 10.7
20 rabies 10.6
21 monkeypox 10.6
22 encephalitis 10.6
23 pontocerebellar hypoplasia, type 1a 10.6 VRK2 VRK1
24 dermatitis 10.5
25 microphthalmia with limb anomalies 10.5 IRF3 IFNA1 EIF2AK2
26 severe combined immunodeficiency 10.5
27 engraftment syndrome 10.5 IFNA1 CSF2
28 herpangina 10.5 IRF3 IL2 IFNA1
29 skin sarcoidosis 10.5 IL2 IFNA1
30 chickenpox 10.4
31 dermatitis, atopic 10.4
32 melanoma 10.4
33 superficial basal cell carcinoma 10.4 IL2 IFNA1
34 allergic hypersensitivity disease 10.4
35 melanoma, cutaneous malignant 10 10.4
36 avian influenza 10.4
37 cytokine deficiency 10.4
38 colon adenocarcinoma 10.3
39 molluscum contagiosum 10.3
40 hepatitis c virus 10.3
41 fibroma 10.3
42 blood coagulation disease 10.3 IL2 IFNA1 CSF2
43 lymphocytic choriomeningitis 10.3
44 skin disease 10.3
45 glioma 10.3
46 glial tumor 10.3
47 keratitis, hereditary 10.3
48 polykaryocytosis inducer 10.3
49 pancreatic cancer 10.3
50 japanese encephalitis 10.3

Graphical network of the top 20 diseases related to Vaccinia:



Diseases related to Vaccinia

Symptoms & Phenotypes for Vaccinia

Symptoms:

12
  • fever
  • rash
  • body aches

MGI Mouse Phenotypes related to Vaccinia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 AZI2 BTRC CD80 CSF2 DUSP3 EIF2AK2
2 immune system MP:0005387 9.36 AZI2 BTRC CD80 CSF2 DUSP3 EIF2AK2

Drugs & Therapeutics for Vaccinia

Drugs for Vaccinia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
2
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 441203 84093
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
5
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
6
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
7
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
8
Pemetrexed Approved, Investigational Phase 2, Phase 3 137281-23-3, 150399-23-8 60843 446556
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
10 Imatinib Mesylate Phase 3 220127-57-1 123596
11 Protein Kinase Inhibitors Phase 3
12 Iron-Dextran Complex Phase 3
13 Immunologic Factors Phase 2, Phase 3
14 Angiogenesis Inhibitors Phase 2, Phase 3
15 Anti-Infective Agents Phase 2, Phase 3
16 Antineoplastic Agents, Immunological Phase 2, Phase 3
17 Antiviral Agents Phase 2, Phase 3
18 Immunosuppressive Agents Phase 2, Phase 3
19 Antimetabolites Phase 2, Phase 3
20 Albumin-Bound Paclitaxel Phase 2, Phase 3
21 Tubulin Modulators Phase 2, Phase 3
22 Antimitotic Agents Phase 2, Phase 3
23
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
24 Vitamin B Complex Phase 2, Phase 3
25 Folic Acid Antagonists Phase 2, Phase 3
26 Folate Phase 2, Phase 3
27 Vitamin B9 Phase 2, Phase 3
28
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
29
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
30
Oxaliplatin Approved, Investigational Phase 1, Phase 2 61825-94-3 43805 6857599 5310940 9887054
31
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
32
Phenol Approved, Experimental Phase 2 108-95-2 996
33
Goserelin Approved Phase 2 65807-02-5 5311128 47725
34
Bicalutamide Approved Phase 2 90357-06-5 2375 56069
35
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
36
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
37
tannic acid Approved Phase 1, Phase 2 1401-55-4
38
Benzocaine Approved, Investigational Phase 1, Phase 2 94-09-7, 1994-09-7 2337
39
Nilutamide Approved, Investigational Phase 2 63612-50-0 4493
40
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 46507594 772
41
Coal tar Approved Phase 1, Phase 2 8007-45-2
42
Testosterone Approved, Experimental, Investigational Phase 2 58-22-0, 481-30-1 10204 6013
43
Flutamide Approved, Investigational Phase 2 13311-84-7 3397
44
Lenograstim Approved, Investigational Phase 2 135968-09-1
45
acetic acid Approved Phase 2 64-19-7 176
46
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
47
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
48
Flucytosine Approved, Investigational Phase 1, Phase 2 2022-85-7 3366
49
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
50
Atezolizumab Approved, Investigational Phase 2 1380723-44-3

Interventional clinical trials:

(show top 50) (show all 269)
# Name Status NCT ID Phase Drugs
1 A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus Completed NCT03472014 Phase 4
2 Phase 4 Study of Speeda® Rabies Vaccinia That Use for Protection the Crowd Bitten by Animals to Three-level Completed NCT01827917 Phase 4
3 Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Recruiting NCT02443623 Phase 4
4 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Completed NCT01158157 Phase 3
5 A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects Completed NCT01144637 Phase 3
6 A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects Completed NCT01913353 Phase 3
7 The Clinical Study of Analgecine for the Treatment of Neuropathic Pain Completed NCT02633618 Phase 3
8 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
9 A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate A Range of Dose Levels of a Heterologous Prime‐Boost Regimen of Ad26.ZEBOV and MVA‐BN®‐Filo in Healthy Adult Subjects Completed NCT02543567 Phase 3
10 A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of a Heterologous Prime‐Boost Regimen Using Three Different Batches of Ad26.ZEBOV and a Single Batch of MVA‐BN®‐Filo in Healthy Adult Subjects Completed NCT02543268 Phase 3
11 A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola Completed NCT02509494 Phase 3
12 An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
13 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, Reactogenicity, and Consistency of a Heterologous 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN®-Filo in Adult Participants Recruiting NCT04228783 Phase 3
14 Evaluation of a Heterologous, Two-dose Preventive Ebola Vaccine for Effectiveness and Safety in the Democratic Republic of the Congo Recruiting NCT04152486 Phase 3
15 Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19 Recruiting NCT04394416 Phase 3 Imatinib;Placebo oral tablet
16 A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy Active, not recruiting NCT02562755 Phase 3 Sorafenib
17 A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Active, not recruiting NCT03699124 Phase 3
18 A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Active, not recruiting NCT02661464 Phase 3
19 A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Terminated NCT01383148 Phase 2, Phase 3 placebo
20 A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers Unknown status NCT00103584 Phase 1, Phase 2
21 INTRALESIONAL IMMUNOTHERAPY WITH A VACCINIA/GM-CSF RECOMBINANT VIRUS IN PATIENTS WITH METASTATIC MELANOMA Unknown status NCT00002817 Phase 1, Phase 2
22 A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
23 A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma. Completed NCT01394939 Phase 1, Phase 2 Irinotecan
24 A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
25 Phase IIa Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) Completed NCT01705223 Phase 2
26 Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31] Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
27 Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis Completed NCT01443260 Phase 1, Phase 2
28 A Phase 2 Open-Label Pilot Safety Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by IV Infusion Followed by Intratumoral Injection Prior to Standard Sorafenib Treatment in Patients With Unresectable Primary Hepatocellular Carcinoma Completed NCT01171651 Phase 2 JX-594 followed by sorafenib
29 Active Specific Intranodal Immunotherapy With a Recombinant Vaccinia Virus Expressing Three Melanoma Associated Epitopes and Two Costimulatory Molecules, Followed by Immunization With Synthetic Melanoma Associated Epitopes. A Phase I/II Trial in Patients With Stages IIb to IV Melanoma Completed NCT00116597 Phase 1, Phase 2
30 A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC) Completed NCT01636284 Phase 2
31 A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment Completed NCT01387555 Phase 2
32 A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults. Completed NCT00050518 Phase 2
33 Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer Completed NCT00003871 Phase 2
34 Treatment Of Patients With Metastatic Melanoma Using Recombinant Vaccinia And Fowlpox Viruses Encoding The Tyrosine Antigen In Combination With Interleukin-2 Completed NCT00054535 Phase 2
35 A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma Completed NCT00429312 Phase 1, Phase 2
36 ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes Completed NCT00133575 Phase 1, Phase 2
37 A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults Completed NCT00038987 Phase 1, Phase 2
38 A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus Completed NCT00063856 Phase 1, Phase 2
39 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl. Completed NCT00316589 Phase 2
40 Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
41 A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults Completed NCT00026611 Phase 2
42 A Combined Phase 1/2a, Exploratory Study of a Therapeutic Vaccine Using an Adenovirus Type 26 Vector Prime and Modified Vaccinia Ankara Boost Combination With Mosaic Inserts in HIV-1 Infected Adults Who Initiated Antiretroviral Treatment During Acute HIV Infection Completed NCT02919306 Phase 1, Phase 2 Placebo
43 A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00050505 Phase 2
44 Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals Completed NCT00914732 Phase 2
45 Immunization of Patients With Metastatic Melanoma Using Recombinant Fowlpox and Vaccinia Viruses Encoding the Tyrosinase Antigen Completed NCT00019734 Phase 2
46 A Randomized, Placebo-Controlled, Dosage-Escalating Phase 2A Study, Double-Blinded With Respect to Assignment to Either Vaccine or Placebo, to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Administered Intramuscularly Followed by an MVA HIV-1 Vaccine Administered at Three Different Dosage Levels and by Three Different Routes to HIV-Uninfected, Healthy, Volunteers. Completed NCT01371175 Phase 2
47 A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Completed NCT00108732 Phase 2 Bicalutamide;Goserelin Acetate
48 A Pilot Study Of Sequential Vaccinations With Recombinant Vaccinia-CEA(6D)-TRICOM, And Recombinant Fowlpox-CEA(6D)-TRICOM (B7.1/ICIAM-1/LFA-3) With Sargramostim (GM-CSF), In Conjunction With Standard Adjuvant Chemotherapy In High Risk Breast Cancer Patients Status Post Surgery With 4+ Or More Lymph Nodes And CEA Expressing Tumors Completed NCT00052351 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
49 The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination Completed NCT00053482 Phase 2
50 A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo

Search NIH Clinical Center for Vaccinia

Cochrane evidence based reviews: vaccinia

Genetic Tests for Vaccinia

Anatomical Context for Vaccinia

The Foundational Model of Anatomy Ontology organs/tissues related to Vaccinia:

19
Skin

MalaCards organs/tissues related to Vaccinia:

40
T Cells, Prostate, Skin, Testes, Breast, Liver, Lung

Publications for Vaccinia

Articles related to Vaccinia:

(show top 50) (show all 13424)
# Title Authors PMID Year
1
Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. 61
32413101 2020
2
Early smallpox vaccine manufacturing in the United States: Introduction of the "animal vaccine" in 1870, establishment of "vaccine farms", and the beginnings of the vaccine industry. 61
32473878 2020
3
EPPIC (Efficient Purification by Parental Inducer Constraint) Platform for Rapid Generation of Recombinant Vaccinia Viruses. 61
32346550 2020
4
Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? 61
32546446 2020
5
Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment. 61
32575351 2020
6
RIP1 kinase activity is critical for skin inflammation but not for viral propagation. 61
31985117 2020
7
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. 61
32322662 2020
8
Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy. 61
32346612 2020
9
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. 61
32199492 2020
10
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans. 61
32554708 2020
11
Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses. 61
32315287 2020
12
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. 61
32199491 2020
13
Comparative sequence and structural analysis of the ORF095 gene, a vaccinia virus A4L homolog of capripoxvirus in sheep and goats. 61
32307603 2020
14
Curcumin Enhances the Antitumoral Effect Induced by the Recombinant Vaccinia Neu Vaccine (rV-neuT) in Mice with Transplanted Salivary Gland Carcinoma Cells. 61
32423101 2020
15
Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection. 61
32510495 2020
16
Magnitude and diversity of immune response to vaccinia virus is dependent on route of administration. 61
32174514 2020
17
A Pool of Eight Virally Vectored African Swine Fever Antigens Protect Pigs Against Fatal Disease. 61
32443536 2020
18
Investigating Viruses During the Transformation of Molecular Biology: Part II. 61
32392458 2020
19
Stable Isotope-Triggered Offset Fragmentation Allows Massively Multiplexed Target Profiling on Quadrupole-Orbitrap Mass Spectrometers. 61
32369372 2020
20
Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma. 61
32019860 2020
21
Preceding Viral Infections Do Not Imprint Long-Term Changes in Regulatory T Cell Function. 61
32433493 2020
22
Benchmarking predictions of MHC class I restricted T cell epitopes in a comprehensively studied model system. 61
32453790 2020
23
Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma. 61
32187960 2020
24
Serological Immunity to Smallpox in New South Wales, Australia. 61
32443405 2020
25
Mutations Near the N Terminus of Vaccinia Virus G9 Protein Overcome Restrictions on Cell Entry and Syncytium Formation Imposed by the A56/K2 Fusion Regulatory Complex. 61
32132239 2020
26
Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice. 61
32001321 2020
27
Rapid protocol of dot-immunnoassay for orthopoxviruses detection. 61
32209339 2020
28
Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer. 61
32461344 2020
29
Influence of the lumpy skin disease virus (LSDV) superoxide dismutase homologue on host transcriptional activity, apoptosis and histopathology. 61
32391749 2020
30
Particle-specific neutralizing activity of a monoclonal antibody targeting the poxvirus A33 protein reveals differences between cell associated and extracellular enveloped virions. 61
32174513 2020
31
Administration with Vaccinia Virus Encoding Canine Parvovirus 2 vp2 Elicits Systemic Immune Responses in Mice and Dogs. 61
32364832 2020
32
Vaccinia Virus as a Master of Host Shutoff Induction: Targeting Processes of the Central Dogma and Beyond. 61
32455727 2020
33
Experimental Evolution To Isolate Vaccinia Virus Adaptive G9 Mutants That Overcome Membrane Fusion Inhibition via the Vaccinia Virus A56/K2 Protein Complex. 61
32132237 2020
34
Allosteric Impact of the Variable Insert Loop in Vaccinia H1-Related (VHR) Phosphatase. 61
32348128 2020
35
Another case of mistaken identity? Vaccinia virus in another live Camelpox vaccine. 61
32334926 2020
36
Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity. 61
32297534 2020
37
Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus. 61
32145202 2020
38
Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer. 61
32127390 2020
39
Leaky scanning translation generates a second A49 protein that contributes to vaccinia virus virulence. 61
32100702 2020
40
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. 61
32325037 2020
41
Investigating the Effect of Encapsulation Processing Parameters on the Viability of Therapeutic Viruses in Electrospraying. 61
32344667 2020
42
The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV. 61
32295168 2020
43
Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity. 61
32344903 2020
44
High risk genotypes for schizophrenia may have been adaptive in the context of smallpox. 61
31935637 2020
45
A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. 61
32272637 2020
46
A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques. 61
32075939 2020
47
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. 61
32235883 2020
48
Phosphorylation of vaccinia-related kinase 1 at threonine 386 transduces glucose stress signal in human liver cells. 61
32266931 2020
49
Correction: A new oncolytic Vaccinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery. 61
32303616 2020
50
A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA). 61
31833037 2020

Variations for Vaccinia

Expression for Vaccinia

Search GEO for disease gene expression data for Vaccinia.

Pathways for Vaccinia

GO Terms for Vaccinia

Cellular components related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.4 WASHC2C VRK1 NLRP1 ITSN1 IRF3 EPS15

Biological processes related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.67 IL2 IFNA1 CSF2 CD80
2 protein autophosphorylation GO:0046777 9.46 VRK2 VRK1 EIF2S1 EIF2AK2
3 viral process GO:0016032 9.36 VRK2 NLRP1 ITSN1 IRF3 EPS15 EIF2AK2
4 Wnt signaling pathway GO:0016055 9.35 VRK3 VRK2 VRK1 CUL1 BTRC
5 dendritic cell differentiation GO:0097028 9.32 CSF2 AZI2
6 mitotic nuclear envelope reassembly GO:0007084 9.26 VRK1 BANF1

Molecular functions related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 WASHC2C VRK3 VRK2 VRK1 NLRP1 ITSN1
2 kinase activator activity GO:0019209 8.62 ITSN1 IL2

Sources for Vaccinia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....